(E) Other individuals whose expertise is 
determined by the Secretary to be beneficial to 
the functioning of the Working Group. 
(d) MEETINGS.—The Working Group shall meet not 
less frequently than annually. 
(e) REPORTING.—Not later than 1 year after the 
date of enactment of this Act, and annually thereafter 
until termination of the Working Group pursuant to sub-
section (g), the Secretary shall— 
(1) submit a report on recommendations re-
ceived under subsection (b)(1) to the Committee on 
Health, Education, Labor, and Pensions of the Sen-
ate and the Committee on Energy and Commerce of 
the House of Representatives; and 
(2) make such report publicly available on the 
website of the Department of Health and Human 
Services. 
(f) APPLICABILITY OF FACA.—The Working Group 
shall be treated as an advisory committee subject to chap-
ter 10 of part I of title 5, United States Code (commonly 
referred to as the ‘‘Federal Advisory Committee Act’’). 
(g) SUNSET.—The Working Group under this section 
shall terminate 5 years after the date of enactment of this 
Act. 
VerDate Sep 11 2014 
02:44 Dec 28, 2023
Jkt 049200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H6731.IH
H6731
ssavage on DSKBC07HB2PROD with BILLS
(h) ENDEMIC FUNGAL DISEASE DEFINED.—In this 
section, the term ‘‘endemic fungal disease’’ means blasto-
mycosis, 
coccidioidomycosis, 
histoplasmosis, 
and 
sparotrichosis. 
SEC. 4. EXPANDING TROPICAL DISEASE PRODUCT PRI-
ORITY REVIEW VOUCHER PROGRAM TO EN-
COURAGE PREVENTION AND TREATMENT OF 
COCCIDIOIDOMYCOSIS. 
Section 524(a)(3) of the Federal Food, Drug, and 
Cosmetic Act (21 U.S.C. 360n(a)(3)) is amended— 
(1) by redesignating subparagraph (S) as sub-
paragraph (T); and 
(2) by inserting after subparagraph (R) the fol-
lowing: 
‘‘(S) Coccidioidomycosis.’’. 
SEC. 5. COMBATING ANTIMICROBIAL RESISTANCE BIO-
PHARMACEUTICAL ACCELERATOR PROGRAM. 
Paragraph (4) of section 319L(c) of the Public 
Health Service Act (42 U.S.C. 247d–7e(c)) is amended 
by adding at the end the following: 
‘‘(H) COMBATING ANTIMICROBIAL RESIST-
ANCE BIOPHARMACEUTICAL ACCELERATOR PRO-
GRAM.— 
‘‘(i) IN
GENERAL.—The Secretary, 
acting through the Director of BARDA, 
VerDate Sep 11 2014 
02:44 Dec 28, 2023
Jkt 049200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H6731.IH
H6731
ssavage on DSKBC07HB2PROD with BILLS
shall implement strategic initiatives, to be 
known as the Combating Antimicrobial Re-
sistance 
Biopharmaceutical 
Accelerator 
Program, including by building on existing 
programs and by awarding contracts, 
grants, and cooperative agreements, or en-
tering into other transactions— 
‘‘(I) to optimize the use of 
antimicrobials in human health set-
tings; 
‘‘(II) to support innovative can-
didate products in preclinical and clin-
ical development that reduce anti-
microbial resistance; and 
‘‘(III) to support research with 
respect to infection prevention and 
control to slow the spread of resistant 
bacteria, fungi, and viruses. 
‘‘(ii) REFERENCES.—Except as other-
wise specified, any reference to the Com-
bating Antibiotic Resistant Bacteria Bio-
pharmaceutical Accelerator or the CARB- 
X program in any statute, Executive order, 
rule, regulation, directive, or other Federal 
document is deemed to be a reference to 
VerDate Sep 11 2014 
02:44 Dec 28, 2023
Jkt 049200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\H6731.IH
H6731
ssavage on DSKBC07HB2PROD with BILLS
the Combating Antimicrobial Resistance 
Biopharmaceutical Accelerator Program 
under this subparagraph. 
‘‘(iii) AUTHORIZATION OF APPROPRIA-
TIONS.— 
‘‘(I) IN GENERAL.—To carry out 
the program under clause (i), there is 
authorized 
to 
be 
appropriated 
$500,000,000 for the period of fiscal 
years 2024 through 2028, to remain 
available until expended. 
‘‘(II) 
REQUIREMENT.—Of 
the 
amounts made available to carry out 
the program under clause (i) for the 
period of fiscal years 2024 through 
2028, not less than 20 percent shall 
be used to support antifungal product 
development.’’. 
Æ 
VerDate Sep 11 2014 
02:44 Dec 28, 2023
Jkt 049200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6301
E:\BILLS\H6731.IH
H6731
ssavage on DSKBC07HB2PROD with BILLS